Efficacy of vonoprazan-based second-lineHelicobacter pylorieradication therapy in patients for whom vonoprazan-based first-line treatment failed
| Autor: | Kouji Toyoda, Yuumi Kusano, Toshikuni Suda, Yasumi Katayama, Shogo Adachi, Itsuo Terauchi, Morio Takahashi, Shigeki Oka, Masaya Tamano |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty biology Vonoprazan business.industry Gastroenterology Lansoprazole Helicobacter pylori biology.organism_classification 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Second line Internal medicine Antibiotic therapy medicine 030211 gastroenterology & hepatology In patient business medicine.drug |
| Zdroj: | Gut. 66:752-753 |
| ISSN: | 1468-3288 0017-5749 |
| DOI: | 10.1136/gutjnl-2016-312028 |
| Popis: | We read with great interest the article by Murakami et al ,1 who performed a randomised, double-blinded study of vonoprazan-based Helicobacter pylori ( H. pylori ) eradication therapy. They showed high success rates for vonoprazan-based first-line and second-line H. pylori treatments, with eradication rates of 92.6% and 98%, respectively. However, the study populations of second-line therapy included patients for whom both lansoprazole-based and vonoprazan-based first-line treatments failed, and those for whom vonoprazan-based first-line therapy failed numbered only 14. In terms of second-line therapy, we think that the eradication rate in patients for whom vonoprazan-based first-line therapy failed is more important. We conducted … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|